Breaking News, Collaborations & Alliances

VantAI, BMS Partner to Accelerate Molecular Glue Drug Discovery

Will leverage VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation.

Author Image

By: Charlie Sternberg

Associate Editor

VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.   The partnership leverages VantAI’s geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics.   VantAI’s technology leverages geometric deep learning t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters